Larimar Therapeutics, Inc.
LRMR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001374690
No open-market purchases or sales by Larimar Therapeutics, Inc. insiders were filed in the last 90 days; 163 institutions reported holding it in 13F filings for Q2 2026, worth $291.4M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Larimar Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 116 | 1 | 103 | −12 |
| Shares | 63.4M | 174.8K | 60.8M | −2.43M (−3.8%) |
| Value | $245.5M | $676.4K | $131.9M | −$113.0M (−46.1%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Larimar Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Opaleye Management Inc. | 1,914,077 | $4.12M | 0.92% |
| Citadel Advisors LLC | 434,286 | $933.7K | 0.00% |
| Nuveen, LLC | 174,788 | $375.8K | 0.00% |
| AQR Capital Management LLC | 112,226 | $241.3K | 0.00% |
| Bridgeway Capital Management, LLC | 103,216 | $221.9K | 0.01% |
| Acadian Asset Management LLC | 53,239 | $113.0K | 0.00% |
| Brevan Howard Capital Management LP | 31,880 | $68.5K | 0.00% |
| Virtus Investment Advisers, Inc. | 26,869 | $57.8K | 0.02% |
| Walleye Capital LLC | 17,166 | $36.9K | 0.00% |
| Ieq Capital, LLC | 16,460 | $35.4K | 0.00% |
| Quadrature Capital Ltd | 10,242 | $21.9K | 0.00% |
| Nisa Investment Advisors, LLC | 3,756 | $8.07K | 0.00% |
| True Wealth Design, LLC | 310 | $667 | 0.00% |
| EverSource Wealth Advisors, LLC | 198 | $426 | 0.00% |
| Russell Investments Group, Ltd. | 193 | $415 | 0.00% |
| Simplex Trading, LLC | 264 | $0 | 0.00% |
Sold out (28)
Institutions that held Larimar Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
Not filed for Q1 2025 yet (1)
Institutions that held Larimar Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 174,788 | $676.4K |